09:22 AM EDT, 10/30/2024 (MT Newswires) -- NovoCure ( NVCR ) reported a Q3 loss Wednesday of $0.28 per diluted share, narrower than a loss of $0.46 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.33.

Net revenue for the quarter ended Sept. 30 was $155.1 million, up from $127.3 million a year earlier.

Analysts surveyed by Capital IQ expected $144 million.

Price: 16.53, Change: -0.09, Percent Change: -0.54